Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vir Biotechnology Inc (NQ: VIR )

6.950 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.950
Bid (Size) 6.500 (11)
Ask (Size) 7.130 (1)
Prev. Close 6.950
Today's Range 6.950 - 6.950
52wk Range 6.560 - 13.09
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
From Vir Biotechnology, Inc.
Via Business Wire

Performance

YTD
-33.87%
-33.87%
1 Month
-8.67%
-8.67%
3 Month
-16.47%
-16.47%
6 Month
-34.74%
-34.74%
1 Year
-29.37%
-29.37%

More News

Read More
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Via Benzinga
What's Next: Vir Biotechnology's Earnings Preview
Via Benzinga
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
Via Benzinga
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
From Vir Biotechnology, Inc.
Via Business Wire
What You Missed On Wall Street This Past Friday
Via Talk Markets
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
From Vir Biotechnology Inc.
Via Business Wire
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Via FinancialNewsMedia
Exposures COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
From Vir Biotechnology, Inc.
Via Business Wire
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
Via InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
From Vir Biotechnology, Inc.
Via Business Wire
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.